DELIVERING THE
PROMISE OF
BIOTHERAPEUTICS
Enabling cell therapy treatment for Type 1 diabetes
More than 9 million people worldwide have Type 1 diabetes.
The Persista Bio™ O2Line™ system is a long-term cell implant that automatically regulates blood sugar like our pancreas does.
Transform
patient
lifestyles
NO painstaking daily management
NO longterm diabetic complications
Persista Bio™ technology enables the promise of biotherapeutics by treating disease with long-term implants that mimic the body’s processes.
This system will replace conventional therapies and enable advanced stem cell therapies without requiring immunosuppression.
No injections, pumps, finger sticks, or sensors.
In preclinical testing:
The O2Line™ prototype has cured diabetic rats, normalizing their blood glucose in 90-day trials.
Persista Bio™ is a seed stage company licensing technology from Cornell University and Giner, Inc.
